The effect of treatment with omalizumab, an anti‐IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma

Background:  Patients with severe persistent asthma who are inadequately controlled despite treatment according to current asthma management guidelines have a significant unmet medical need. Such patients are at high risk of serious exacerbations and asthma‐related mortality.

[1]  E. Chilvers,et al.  Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate‐to‐severe) allergic asthma , 2004, Allergy.

[2]  L. Boulet,et al.  Efficacy and tolerability of anti‐immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR , 2004, Allergy.

[3]  J. Bousquet,et al.  Efficacy and safety of a recombinant anti‐immunoglobulin E antibody (omalizumab) in severe allergic asthma , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[4]  J. Bousquet,et al.  Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. , 2004, Chest.

[5]  W. Roche,et al.  Asthma deaths; persistent and preventable mortality , 2003, Histopathology.

[6]  W. Lumry,et al.  Omalizumab is effective in the long-term control of severe allergic asthma. , 2003, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  H. Windom,et al.  Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. , 2003, The Journal of allergy and clinical immunology.

[8]  Charles A. Johnson,et al.  Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma , 2003, Current medical research and opinion.

[9]  T. Casale,et al.  Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. , 2003, The Journal of allergy and clinical immunology.

[10]  E. Matsui,et al.  OMALIZUMAB PROVIDES LONG-TERM CONTROL IN PATIENTS WITH MODERATE-TO-SEVERE ALLERGIC ASTHMA , 2003 .

[11]  A. Togias,et al.  Risk factors for recurrent asthma hospital visits and death among a population of indigent older adults with asthma. , 2002, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[12]  J. Thirlwell,et al.  The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma , 2002, European Respiratory Journal.

[13]  C. Camargo,et al.  A prospective multicenter study of factors associated with hospital admission among adults with acute asthma. , 2002, The American journal of medicine.

[14]  C. Camargo,et al.  A prospective multicenter study of patient factors associated with hospital admission from the emergency department among children with acute asthma. , 2002, Archives of pediatrics & adolescent medicine.

[15]  W. Busse,et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. , 2001, The Journal of allergy and clinical immunology.

[16]  J. Abisheganaden,et al.  A new asthma severity index: a predictor of near-fatal asthma? , 2001, The European respiratory journal.

[17]  R. Townley,et al.  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. , 2001, The European respiratory journal.

[18]  H. Milgrom,et al.  Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab). , 2001, Pediatrics.

[19]  J. Bousquet,et al.  Efficacy of Omalizumab, an Anti-immunoglobulin E Antibody, in Patients with Allergic Asthma at High Risk of Serious Asthma-related Morbidity and Mortality* , 2001, Current medical research and opinion.

[20]  S. Leeder,et al.  Risk factors for asthma deaths: a population‐based, case‐control study , 1999, Australian and New Zealand journal of public health.

[21]  M. Burr,et al.  A confidential inquiry into asthma deaths in Wales. , 1999, Thorax.

[22]  S. Vedal,et al.  Risk factors for near-fatal asthma. A case-control study in hospitalized patients with asthma. , 1998, American journal of respiratory and critical care medicine.

[23]  P. Hessel,et al.  Features that distinguish those who die from asthma from community controls with asthma. , 1998, The Journal of asthma : official journal of the Association for the Care of Asthma.

[24]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .